Physician profile
Michael Nute
NPI 1376597229
$6,097.68
in general payments reported to CMS, 2019-2025
28 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $162 · 2021: $140 · 2022: $4,836 · 2023: $334 · 2024: $177 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vilex LLC | $2,478.96 | 2022 | |
| Medartis INC. | $2,225.00 | 2022 | |
| Stryker Corporation | $243.07 | 2022-2025 | Bio4, Prophecy, Ortholoc 2 Lapifuse |
| Sanara Medtech INC. | $140.27 | 2021 | |
| Polynovo North America LLC | $112.98 | 2020 | |
| Treace Medical Concepts, INC. | $104.56 | 2024-2025 | |
| Next Science LLC | $96.70 | 2023 | Surgx, Xperience, Blastx |
| Wright Medical Technology, INC. | $93.78 | 2019 | |
| Aroa Biosurgery Incorporated | $75.00 | 2023 | |
| Avita Medical Americas, LLC | $67.48 | 2025 | Recell, Cohealyx, Permeaderm |
| Fusion Orthopedics USA, LLC | $56.78 | 2025 | |
| Horizon Therapeutics Plc | $49.42 | 2019-2020 | |
| Nevro Corp. | $44.92 | 2022-2023 | Senza |
| Acera Surgical, INC. | $44.57 | 2024 | Restrata Wound Matrix |
| Depuy Synthes Sales INC. | $33.60 | 2023 | Motoband |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $31.08 | 2022 | |
| Integra Lifesciences Corporation | $25.49 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kerecis Limited | $25.30 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Axogen | $24.21 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Organogenesis INC. | $20.67 | 2022 | |
| Abbvie INC. | $19.38 | 2022 | |
| Medtronic, INC. | $16.35 | 2023 | Intellis Adaptivestim |
| Nabriva Therapeutics, Plc | $14.76 | 2022 | |
| Paragon 28, INC. | $14.70 | 2020 | |
| Assertio Therapeutics, INC. | $14.28 | 2019 | |
| Enduromed, LLC | $12.78 | 2023 | |
| Merck Sharp & Dohme LLC | $11.59 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.